Gilead Sciences (NASDAQ:GILD) Shares Gap Down - Should You Sell?

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $113.00, but opened at $109.89. Gilead Sciences shares last traded at $111.24, with a volume of 1,628,933 shares trading hands.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group boosted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Performance

The firm's 50 day moving average is $105.36 and its 200 day moving average is $101.86. The stock has a market cap of $136.22 billion, a P/E ratio of 296.34, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the firm posted ($1.32) EPS. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.89%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,000 shares of company stock valued at $4,630,310. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in the business. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at $25,000. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors raised its position in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.